Journal ArticleDOI
Anti-cancer drugs
Reads0
Chats0
About:
This article is published in Current Pharmaceutical Design.The article was published on 2005-03-31. It has received 882 citations till now. The article focuses on the topics: Introductory Journal Article.read more
Citations
More filters
Journal ArticleDOI
The status of platinum anticancer drugs in the clinic and in clinical trials.
TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI
Natural products to drugs: natural product derived compounds in clinical trials
Mark S. Butler,Mark S. Butler +1 more
TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.
Journal ArticleDOI
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John Ramage,A Ahmed,J Ardill,N.D.S. Bax,David J. Breen,Martyn Caplin,Pippa Corrie,J Davar,Albert Davies,Val Lewington,Tim Meyer,John Newell-Price,Graeme J. Poston,N. Reed,Andrea Rockall,William P. Steward,Rajesh V. Thakker,C. Toubanakis,Juan W. Valle,Caroline S. Verbeke,Ashley B. Grossman +20 more
TL;DR: These guidelines update previous guidance published in 2005 and have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology and others.
Journal ArticleDOI
Cellular distribution and functions of P2 receptor subtypes in different systems.
TL;DR: This review is aimed at providing readers with a comprehensive reference article about the distribution and function of P2 receptors in all the organs, tissues, and cells in the body.
Journal ArticleDOI
Natural products: an evolving role in future drug discovery.
Bhuwan B. Mishra,Vinod K. Tiwari +1 more
TL;DR: The present review describes natural products, semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious, immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.
References
More filters
Journal ArticleDOI
Synthesis of apoptosis-inducing iminophosphorane organogold(III) complexes and study of their interactions with biomolecular targets.
Neha Shaik,Alberto Martínez,Idline Augustin,Hugh Giovinazzo,Armando Varela-Ramirez,Mercedes Sanaú,Renato J. Aguilera,María Contel +7 more
TL;DR: Complexes 1-5 have been tested as potential anticancer agents, and their cytotoxicity properties were evaluated in vitro against HeLa human cervical carcinoma and Jurkat-T acute lymphoblastic leukemia cells.
Journal ArticleDOI
Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
María Pilar Sánchez-Bailón,Annarica Calcabrini,Annarica Calcabrini,Daniel Gomez-Dominguez,Beatriz Morte,Esther Martín-Forero,Gonzalo Gómez-López,Agnese Molinari,Kay Uwe Wagner,Jorge Martín-Pérez +9 more
TL;DR: The results show the importance of SFKs catalytic activity for MDA-MB-231 proliferation, migration and invasiveness and illustrate that SU6656 acts as dualSFKs and Aurora B kinase inhibitor, suggesting its possible use as a therapeutic agent in breast cancer.
Journal ArticleDOI
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
TL;DR: The most recent clinical trials data pertaining to new cytotoxic drugs including patupilone, telcyta, and trabectedin, as well as those of small molecules and inhibitors of the EGFR and VEGF receptor families are reviewed.
Journal ArticleDOI
Development of secreted proteins as biotherapeutic agents.
TL;DR: An overview on the features and functions of human secreted proteins and peptides, as well as strategies by which to discover additional therapeutic proteins from the human ‘secretome’ are provided.
Journal ArticleDOI
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
Kathleen N. Moore,Thomas J. Herzog,Sharyn N. Lewin,Robert L. Giuntoli,Deborah K. Armstrong,Rodney P. Rocconi,Whitney A. Spannuth,Michael A. Gold +7 more
TL;DR: CT compares favorably with PT and demonstrates a superior overall response rate, because of its ease of administration and improved toxicity profile, CT should be considered in the treatment of advanced, recurrent or progressive cervical cancer.